A best evidence topic in thoracic surgery was written according to a structured protocol. The question addressed was which diagnostic modality wcomputed tomography (CT), positron emission tomography (PET), combination PETyCT and magnetic resonance imaging (MRI)x provides the best diagnostic and staging information in patients with malignant pleural mesothelioma (MPM). Overall, 61 papers were found using the reported search, of which 14 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results are tabulated. We conclude that fluorodeoxyglucose (FDG)-PET is superior to MRI and CT but inferior to PET-CT, in terms of diagnostic specificity, sensitivity and staging of MPM. Four studies reported outcomes using FDG-PET to diagnose MPM. PET diagnosed MPM with high sensitivity (92%) and specificity (87.9%). Mean standardised uptake value (SUV) was higher in malignant than benign disease (4.91 vs. 1.41, P-0.0001). Lymph node metastases were detected with higher accuracy (80% vs. 66.7%) compared to extrathoracic disease. Three studies assessed the utility of PET-CT to diagnose MPM. Mean SUV was higher in malignant than benign disease (6.5 vs. 0.8, P-0.001). MPM was diagnosed with high sensitivity (88.2%), specificity (92.9%) and accuracy (88.9%). PET-CT had low sensitivity for stage N2 (38%) and T4 (67%) disease. CT-guided needle biopsy definitively diagnosed MPM after just one biopsy (100% vs. 9%) much more often than a 'blind' approach. CT had a lower success rate (92% vs. 100%) than thoracoscopic pleural biopsy but was equivalent to MRI in terms of detection of lymph node metastases (Ps0.85) and visceral pleural tumour (Ps0.64). CT had a lower specificity for stage II (77% vs. 100%, P-0.01) and stage III (75% vs. 100%, P-0.01) disease compared to PET-CT. Overall, the high specificity and sensitivity rates seen with open pleural biopsy make it a superior diagnostic modality to CT, MRI or PET for diagnosing patients with MPM.
Introduction
A best evidence topic in thoracic surgery was constructed according to a structured protocol. This is fully described in the ICVTS w1x.
Three-part question
In wpatients with malignant mesotheliomax is wFDG-PETx superior to wCT or MRIx in terms of wdiagnostic specificity, sensitivity and tumour stagingx.
Clinical scenario
You are at a multidisciplinary meeting and review a 61-year-old retired plumber, with past asbestos exposure, who presented with chronic cough and shortness of breath. Computed tomography (CT)-scan identified a right-sided pleural effusion with thickening of the parietal pleura and loss of volume on the affected side. You suspect it could be malignant mesothelioma but are unsure as to which *Corresponding author. Tel.: q44 75 15542899; fax: q44 20 71881016. E-mail address: marco.scarci@mac.com (M. Scarci). diagnostic modality would provide a definitive diagnosis and stage the disease accurately. You resolve to check the literature yourself.
Search strategy
Medline search 1950 to August 2010 was performed using the OVID interface wmalignant pleural mesothelioma.mpx AND wimaging.mpx AND wdiagnosis.mpx.
Search outcome
Sixty-one papers were found using the reported search. From these, 14 papers provided the best evidence to answer the clinical question. These are presented in Table 1 . In addition, the reference list of each paper was searched.
Results
Four studies reported outcomes using fluorodeoxyglucosepositron emission tomography (FDG-PET) to diagnose suspected malignant pleural mesothelioma (MPM). Bernard et al. w2x diagnosed MPM with high sensitivity (92%) and Downloaded from https://academic.oup.com/icvts/article-abstract/12/2/254/742618 by guest on 31 October 2018 I. Zahid et al. / Interactive CardioVascular and Thoracic Surgery 12 (2011) FDG-PET, fluorodeoxyglucose-positron emission tomography; SUV, standardised uptake value; MPM, malignant pleural mesothelioma; ROC, area under receiver operating curve; CT, computed tomography; VACT, video-assisted cervical thoracoscopy; F-FDG-CI, FDG-dual head gamma-camera coincidence imaging; MRI, magnetic resonance imaging; NS, not significant. specificity (75%). Malignant and benign disease were accurately distinguished by differences in mean standardised uptake value (SUV) (4.91"2.90 vs. 1.41"0.63, P-0.0001) and tumourylung ratios (12.97 vs. 2.69, P-0.0001). Lymph node metastases were detected with high accuracy (80%). Yamamoto et al. w3x observed large increases in delayed (120 min post-F-FDG injection) compared to early (60 min 18 post-F-FDG injection) SUV measurements in malignant 18 (7.72 vs. 9.39, P-0.001) but not in benign disease (2.92 vs. 3.27, PsNS). Similarly, Mavi et al. w4x reported lower mean SUV (1.6 vs. 5.0 vs. 4.6, P-0.0001) with benign pleural disease compared to newly diagnosed MPM and recurrent MPM, respectively. Flores w5x used FDG-PET to identify N2 disease with an accuracy of 78% and reported a higher mean SUV (8.6 vs. 5.3) than N0yN1 disease. Extrathoracic disease was identified with low accuracy (66.7%). PET was sensitive for only 19% of T4 tumours.
Three studies used a combination of FDG-PET and CT to diagnose MPM. Yildrim et al. w6x identified MPM with high specificity (92.9%) and sensitivity (88.2%). Large differences were observed between the mean SUV (6.5 vs. 0.8, P-0.001) of malignant and benign disease. Tan et al. w7x showed that PET-CT identified recurrence of MPM with high accuracy (88.9%), specificity (100%) and sensitivity (94%) with a mean SUV of 8.9"4.0. Erasmus et al. w8x found FDG-PET-CT determined tumour T stage and N stage with accuracies of 63% and 35%, respectively. PET-CT understaged tumour T and N stage in 29% and 35% of patients and overstaged disease in 8% and 29% of patients, respectively. PET-CT had low sensitivity for T4 (67%) and N2 (38%) disease with most errors occurring due to failure to identify transpericardial and transdiaphragmatic disease. Two studies observed outcomes of pleural biopsy and thoracoscopy in diagnosing patients with MPM. Attanoos and Gibbs w9x compared the effectiveness of open pleural (ns21), CTguided closed (ns5) and 'blind' closed percutaneous needle biopsies (ns5). CT-guided biopsy made a definitive diagnosis after just one biopsy (100% vs. 9%) much more often than a 'blind' approach, which produced an inadequate sample in 32% of patients. Open pleural biopsy was 95% sensitive and 100% specific for MPM and biopsied larger tissue samples (range 60-290 mm vs. 1-15 mm) than the closed approach. Chamberlain et al. w10x conducted videoassisted cervical thoracoscopy (VACT) (ns15) and compared it to conventional preoperative staging protocols (ns26). VACT produced a success rate of 76.9% from a right-sided approach (ns13) but a 0% success rate from a left-sided approach (ns3) due to operative difficulties. VACT greatly reduced time to radical surgery (28 vs. 87 days, P-0.001) compared to conventional preoperative MPM staging protocols.
Five studies compared the effectiveness of CT to other diagnostic modalities in identifying MPM. Gerbaudo et al. w11x compared CT to FDG-dual head gamma-camera coincidence imaging (F-FDG-CI). F-FDG-CI diagnosed MPM with equivalent specificity (80% vs. 80%) but greater sensitivity (97% vs. 83%) and accuracy (94% vs. 82%) than CT. There was strong agreement of F-FDG-CI (94%, ks0.77, P-0.0001) and CT (82%, ks0.47, P-0.003) with pleural biopsy results. F-FDG-CI detected diffuse chest wall disease (100% vs. 33%) and mediastinal lymph node metastases (88% vs. 75%) more accurately than CT. Heelan et al. w12x compared CT with magnetic resonance imaging (MRI) in 65 patients. With regards to areas under receiver operating curves (ROC), CT was equivalent to MRI in terms of detection of lymph node metastases (0.49 vs. 0.51, Ps0.85) and visceral pleural tumour (0.67 vs. 0.58, Ps0.64) but inferior to MRI at detecting disease invading the diaphragm (0.55 vs. 0.82, Ps0.01) and endothoracic fascia (0.46 vs. 0.69, Ps0.05). Grossebner et al. w13x analysed 25 patients and showed that CT had a lower success rate (92% vs. 100%) than thoracoscopic pleural biopsy. Nanni et al. w14x compared FDG-PET with CT and reported high concordance rates (60%) between the two modalities. PET upstaged disease in 13% and downstaged disease in 27% of patients, which resulted in a change in the management protocol of 20% of patients. Plathow et al. w15x compared diagnostic utility of PET-CT with CT, PET and MRI in 54 patients. PET-CT had a higher accuracy than CT, PET and MRI for stage II (100% vs. 77% vs. 86% vs. 80%, P-0.01) and stage III (100% vs. 75% vs. 83% vs. 90%, P-0.01) tumours. CT demonstrated much lower sensitivities (75% vs. 91% vs. 83% vs. 100%) at detecting MPM than MRI, PET and PET-CT, respectively.
Clinical bottom line
There are many diagnostic modalities to identify patients with malignant mesothelioma. Currently there is no consensus as to which single modality should be used to confirm diagnosis prior to surgery. The studies above have shown that PET-CT is superior to FDG-PET, MRI and CT in terms of specificity and sensitivity of disease detection and staging of MPM. However, surgical pleural biopsy still provides the most accurate definitive diagnosis but is a more invasive procedure than PET-CT.
